Does Investing in Art Pay Off?
Many high-net-worth individuals have a strong interest in investing outside of the usual stock market. There are all kinds of things people can invest in, including luxury cars, real estate, horses, jewelry and of course artwork. The artwork is one of the most common collection items that the wealthy invest in and many high-net-worth individuals have increased their net worth through prudent investments in art. However, investing in the artwork is not cut and dry. It doesn’t always prove fruitful and there are arguments both for and against this endeavor.
Are the Return Numbers Actually Inflated?
In fact, according to a study released earlier this year, investing in the art may not be nearly as lucrative as those in the industry have led us to believe. In June of this year the Luxembourg School of Finance at the University of Luxembourg released the findings from research it did on the returns of fine art. That research indicated that even though the Index of Fine Art Sales has shown a 10 percent yearly average return on all art investments over the last 40 years, those numbers are in fact not nearly that high. Based on their research, which was taken from the Blouin Art Sales Index, which is the most complete auction database available, the actual average return from 1960 to 2013 was only 6.3 percent. The researchers also concluded that the mere fact of holding an art fund in an investment portfolio does not improve the likelihood that a given portfolio will outperform.
More Risk Investing in Art?
There is another possible downside for those considering investing in art. Based on the information gathered from the Blouin Art Sales Index, the researchers calculated a score of 0.11 on the Sharpe Ratio, which is used to calculate the risk-adjusted return. The previous value that had been reported was 0.27, which is much more favorable because the higher the value of the Sharpe Ratio the better the risk-adjusted return.
Why the Discrepancy?
So how are the estimated numbers from the art investing industry so far apart from the actual results? The researchers say the main cause is that investors and dealers have been guilty of selection bias. This happens because paintings that are in high demand usually end up being auctioned off more often and they sell for a lot more money, which gives them an upward bias. In addition, art owners typically sell their paintings that have increased the most in value. These numbers are then incorrectly applied to the value of paintings that sell less frequently or that don’t sell at all.
Make Sure You Love it
Of course, there are many arguments both for and against investing in art. Some investors have had a lot of success, while many others have ended up on the wrong side of art investment. If you are considering investing in art, then one simple rule to live by is to always purchase something because you love it and you know you’ll be happy with it even if you never do sell it.
//phys.org/news/2016-06-invest-art-fine-overestimated.html
//www.huffingtonpost.com/artinfo/does-investing-in-art-make-sense_b_2663745.html
Armin Tahmasbi | Encapsulate
I’m a young entrepreneur and a Ph.D. candidate in Biomedical Engineering program at the University of Connecticut, working on “Drug Delivery Systems, Self-Assembled Nanoparticles & Microfluidic Devices”, in Storrs, CT, US. I’m working in Self-Assembled Functional Nanomaterials Laboratory, under the supervision of Prof. Mu-Ping Nieh on “Drug Delivery Systems for cancer therapy”. We’re developing a universal platform for encapsulating and smart delivery of a wide range of drug molecules and
Spencer Jones | Lineus Medical
Spencer worked for 3 years in direct patient care as a Certified Nursing Assistant, Licensed Practical Nurse, and as a Registered Nurse. Frustrated with the inefficiencies plaguing the healthcare system, he was determined to play a role in improving the delivery of healthcare. In 2014, Spencer won the annual ARK Challenge, an Arkansas based business accelerator. The product he developed was a dual lumen peripheral IV called the BVAD, which focuses on painless and uncontaminated blood draws.
Adeel Malik | CEO of Clearstep
While studying finance and neurobiology in undergrad, Adeel spent his time doing neuro-immunology research at the Johns Hopkins Hospital, contributing to several academic publications. After undergrad, Adeel was a strategy & analytics consultant with Accenture for several years where he worked with some of the largest institutions in healthcare across pharma, health tech, health systems, and retail clinics. Adeel’s skills in healthcare analytics, operations, sales, and his breadth of experience
Yael Katz | How BrainCheck is Democratizing Cognitive Health
Dr. Yael Katz is the co founder and CEO of Braincheck, a healthcare technology company focused on making cognitive health assessments more accessible. Prior to co founding Braincheck, Yael was VP of ecommerce at JW Player and a post doctoral research fellows at Princeton University. She received a Ph.D in in Biological Sciences focusing on Computational and Experimental Neuroscience from Northwestern University.Alan What brought you to co founding Braincheck? Yael If a person has a concern that